This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Latest comment: 12 years ago2 comments2 people in discussion
This article suggests a mechanism of action for this group of compounds that is not supported by the majority of peer reviewed publications on the subject. There is in fact no consensus regarding this matter. Furthermore, it appears that this article does not acknowledge another group of compounds that are also characterized as dopaminergic stabilizers, i.e. partial D2 receptor agonists such as aripiprazole and (-)-3-PPP.
80.216.147.122 (talk) 18:55, 29 January 2011 (UTC)Reply
The whole article was rather NPOV and I suspect it was written by someone involved in the drug's development. I've edited it as far as I'm confident, to restore NPOV, but I'm not enough of a pharmacologist to correct the mechanism section. Please could you or someone suitably knowledgeable edit this section? Dubbin (talk) 13:11, 11 December 2011 (UTC)Reply